Trial · NCT01576523
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Modeled C1-esterase Inhibitor Functional Activity Trough Level | CSL830 (Low Dose) | 30.3 | Standard Deviation 9.07 | percent functional activity | |
| Modeled C1-esterase Inhibitor Functional Activity Trough Level | CSL830 (Medium Dose) | 45.9 | Standard Deviation 14.35 | percent functional activity | |
| Modeled C1-esterase Inhibitor Functional Activity Trough Level | CSL830 (High Dose) | 80.6 | Standard Deviation 23.47 | percent functional activity | |
| As-observed C1-esterase Inhibitor Functional Activity Trough Level | CSL830 (Low Dose) | 31.7 | Standard Deviation 9.97 | percent functional activity | |
| As-observed C1-esterase Inhibitor Functional Activity Trough Level | CSL830 (Medium Dose) | 44.3 | Standard Deviation 17.73 | percent functional activity | |
| As-observed C1-esterase Inhibitor Functional Activity Trough Level | CSL830 (High Dose) | 80.5 | Standard Deviation 24.92 | percent functional activity | |
| C1-esterase Inhibitor Concentration Trough Level | CSL830 (Low Dose) | 0.06 | Standard Deviation 0.024 | mg/mL | |
| C1-esterase Inhibitor Concentration Trough Level | CSL830 (Medium Dose) | 0.15 | Standard Deviation 0.130 | mg/mL | |
| C1-esterase Inhibitor Concentration Trough Level | CSL830 (High Dose) | 0.23 | Standard Deviation 0.158 | mg/mL | |
| C4 Concentration Trough Level | CSL830 (Low Dose) | 11.1 | Standard Deviation 4.45 | mg/dL | |
| C4 Concentration Trough Level | CSL830 (Medium Dose) | 14.1 | Standard Deviation 5.28 | mg/dL | |
| C4 Concentration Trough Level | CSL830 (High Dose) | 18.4 | Standard Deviation 6.55 | mg/dL | |
| Change From Baseline in C1-esterase Inhibitor Functional Activity | CSL830 (Low Dose) | 16.4 | Standard Deviation 7.41 | percent functional activity | |
| Change From Baseline in C1-esterase Inhibitor Functional Activity | CSL830 (Medium Dose) | 33.2 | Standard Deviation 11.32 | percent functional activity | |
| Change From Baseline in C1-esterase Inhibitor Functional Activity | CSL830 (High Dose) | 63.3 | Standard Deviation 21.33 | percent functional activity | |
| Change From Baseline in C1-esterase Inhibitor Concentration | CSL830 (Low Dose) | 0.02 | Standard Deviation 0.018 | mg/mL | |
| Change From Baseline in C1-esterase Inhibitor Concentration | CSL830 (Medium Dose) | 0.05 | Standard Deviation 0.029 | mg/mL | |
| Change From Baseline in C1-esterase Inhibitor Concentration | CSL830 (High Dose) | 0.14 | Standard Deviation 0.047 | mg/mL | |
| Change From Baseline in C4 Concentration | CSL830 (Low Dose) | 4.3 | Standard Deviation 3.00 | mg/dL | |
| Change From Baseline in C4 Concentration | CSL830 (Medium Dose) | 5.6 | Standard Deviation 11.90 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01576523/results